Evidence map›Paper›PMID 30683129›Full record

ArticleJournal of nanobiotechnology2019

Tri-mannose grafting of chitosan nanocarriers remodels the macrophage response to bacterial infection.

Juan Manuel Coya, Laura De Matteis, Alexandre Giraud-Gatineau, Anne Biton, Inés Serrano-Sevilla, Anne Danckaert, Marie-Agnès Dillies, Brigitte Gicquel, Jesus M De la Fuente, Ludovic Tailleux

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Glycosylated-Chitosan Derivatives: A Systematic Review.Molecules (Basel, Switzerland) · 2020
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Juan Manuel CoyaMycobacterial Genetics Unit, Institut Pasteur, Paris, France.
Laura De MatteisInstituto de Nanociencia de Aragon, Universidad de Zaragoza and CIBER-BBN, Saragossa, Spain.
Alexandre Giraud-GatineauMycobacterial Genetics Unit, Institut Pasteur, Paris, France.
Anne BitonInstitut Pasteur - Bioinformatics and Biostatistics Hub - C3BI, USR 3756 IP CNRS, Paris, France.
Inés Serrano-SevillaCIBER-BBN, Instituto de Salud Carlos III, Madrid, Spain.
Anne DanckaertUtechS Photonic BioImaging (Imagopole)-Citech, Institut Pasteur, Paris, France.
Marie-Agnès DilliesInstitut Pasteur - Bioinformatics and Biostatistics Hub - C3BI, USR 3756 IP CNRS, Paris, France.
Brigitte GicquelMycobacterial Genetics Unit, Institut Pasteur, Paris, France.
Jesus M De la FuenteInstituto de Ciencia de Materiales de Aragón (ICMA), CSIC-Universidad de Zaragoza, and CIBER-BBN, Edificio I+D, Calle Mariano Esquillor s/n, 50018, Saragossa, Spain. jmfuente@unizar.es.
Ludovic TailleuxMycobacterial Genetics Unit, Institut Pasteur, Paris, France. ludovic.tailleux@pasteur.fr.ORCID http://orcid.org/0000-0003-3931-1052
Centre National de la Recherche Scientifique · FRInstitut Pasteur · FRUniversidad de Zaragoza · ES

Funding

FP7 Health 604237
6 · The paper itself

Abstract

backgroundInfectious diseases are still a leading cause of death and, with the emergence of drug resistance, pose a great threat to human health. New drugs and strategies are thus urgently needed to improve treatment efficacy and limit drug-associated side effects. Nanotechnology-based drug delivery systems are promising approaches, offering hope in the fight against drug resistant bacteria. However, how nanocarriers influence the response of innate immune cells to bacterial infection is mostly unknown.

resultsHere, we used Mycobacterium tuberculosis as a model of bacterial infection to examine the impact of mannose functionalization of chitosan nanocarriers (CS-NCs) on the human macrophage response. Both ungrafted and grafted CS-NCs were similarly internalized by macrophages, via an actin cytoskeleton-dependent process. Although tri-mannose ligands did not modify the capacity of CS-NCs to escape lysosomal degradation, they profoundly remodeled the response of M. tuberculosis-infected macrophages. mRNA sequencing showed nearly 900 genes to be differentially expressed due to tri-mannose grafting. Unexpectedly, the set of modulated genes was enriched for pathways involved in cell metabolism, particularly oxidative phosphorylation and sugar metabolism.

conclusionsThe ability to modulate cell metabolism by grafting ligands at the surface of nanoparticles may thus be a promising strategy to reprogram immune cells and improve the efficacy of encapsulated drugs.

Indexed as

Bacterial InfectionsCells, CulturedChitosanDrug CarriersDrug Delivery SystemsHost-Pathogen InteractionsHumansImmunity, InnateMacrophagesMannoseMetabolic Networks and PathwaysMycobacterium tuberculosisNanoparticlesPhagocytosisTranscriptomeChitosanDrug CarriersMannoseChitosan nanocarriersHost responseMacrophagesMycobacterium tuberculosisSurface grafting

Identifiers

PMID30683129
PMCPMC6346558
OpenAlexW2921355508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.